Plant Health Care H1 revenue growth partially offset by currency headwinds

Plant Health stated that revenues had grown 13% to $3.5m in the six months ended 30 June, driven by increased sales in the US and Europe.

However, the AIM-listed firm also cautioned that gross margins had contracted from 59% to 56% due to currency effects and added that operating expenses had increased 18% throughout the half to $4.7m.

Cash used in operations decreased 29% to $1.5m.

Chief executive Dr Christopher Richards said: "The world remains an uncertain place, as shown by the effects of Covid-19 on sales in Brazil and Mexico.

"The board expects trading for the full year to be in line with management expectations."

As of 1045 BST, Plant Health shares were down 4.79% at 13.90p.